The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

The $10.50-per-share deal values CheckMate at around $250 million, and revolves around the toll-like receptor-9 (TKR9) agonist ... as well as head and neck cancer. Readouts from phase 2 studies ...